Amgen Ventures
As a company formed with venture capital funding more than 25 years ago, we understand the challenges faced by early-stage biotechnology companies. In 2004, we announced the formation of Amgen Ventures, our corporate venture capital fund. With an initial investment of $100 million, the fund is designed to provide emerging biotechnology companies with resources to develop pioneering discoveries focused on human therapeutics. Amgen Ventures reflects Amgen's commitment to helping patients by transforming cutting-edge scientific discoveries into novel treatments for serious illness.
As an important component of Amgen’s overall outreach strategy, Amgen Ventures invests in early-stage biotechnology companies focused on discovering and developing human therapeutics. The fund, which focuses primarily on areas of current therapeutic interest to Amgen, offers early-stage companies access to our extensive capabilities while providing us with insight into external research innovations that may pave the way for future collaborations.
Amgen Ventures, based in San Francisco, also leverages existing Amgen sites, including Seattle, Thousand Oaks, and Cambridge.